{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-286642","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2025-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.659008+00:00","generated_at":"2026-05-16T18:31:18.657909+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"HCW Biologics licenses HCW11-006 to Trimmune; $7M upfront (half cash, half equity)","bullets":["Amended License, Research & Co-Development Agreement with Beijing Trimmune for HCW11-006 in vivo applications.","$7.0M upfront fee: $3.5M cash at closing, $3.5M in Trimmune equity.","Company retains payment-free option to recapture rights for US, Canada, Central & South America after Phase 1.","Trimmune responsible for all R&D, manufacturing, clinical, regulatory, commercialization costs in its territory.","If closing not completed by Jan 16, 2026, all IP and rights to HCW11-006 return to HCW."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-286642","json":"https://secwatch.observer/filing/0001193125-25-286642.json","markdown":"https://secwatch.observer/filing/0001193125-25-286642.md","text":"https://secwatch.observer/filing/0001193125-25-286642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000119312525286642/0001193125-25-286642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000119312525286642/hcwb-20251117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:31:18.657909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}